▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #511 by analyst upside · 2026-09-16
HYPD
Hyperion DeFi, Inc.
Healthcare · Market Cap $51M · P/E 0x
ANALYST PRICE TARGET
+198.6%
implied upside to consensus target
Current Price $3.29
Consensus Target $9.82
Bull Target $11.2
Bear Target $8.45
Analysts Covering 2
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
2
Hold
0
Sell
0
52-Week Low $2.34
52-Week High $13.71
YTD Return -8.1%
FUNDAMENTALS
Market Cap $51M
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-3.46
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $1M
Profit Margin 474.9%
52-WEEK RANGE
52-Week Low $2.34
52-Week High $13.71
Current Price $3.29
Bear Target $8.45
Bull Target $11.2
● Now $3.29 ● Target $9.82
TRADING DATA
Avg Volume 500K
YTD Return -8.1%
Analyst Count 2
Consensus Buy
Upside to Target +198.6%
Last Updated 2026-09-16

ANALYST SUMMARY

Hyperion DeFi, Inc. (HYPD) is currently trading at $3.29 with a Wall Street consensus price target of $9.82, implying potential upside of 198.6% over the next 12 months. 2 analysts currently cover HYPD, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $11.2, while the most cautious has a target of $8.45.

HYPD operates in the Healthcare sector with a market capitalisation of $51M. The stock is down 8.1% year-to-date and is currently trading near the lower end of its 52-week range of $2.34 – $13.71.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ATNM +180.0%
Actinium Pharmaceuticals, Inc.
$39M · P/E 3.7x · Buy
ELOX +121.0%
Eloxx Pharmaceuticals, Inc.
$63M · P/E 4.6x · Buy
CCLD +198.8%
CareCloud, Inc.
$87M · P/E 29.3x · Buy
BTMD +87.9%
biote Corp.
$47M · P/E 9.9x · Buy
DXR +79.4%
Daxor Corporation
$65M · P/E 6.7x · Strong Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for HYPD, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-09-10 40% win rate (10 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-09-08 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-08-13 33% win rate (6 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-08-13 40% win rate (10 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-08-11 33% win rate (6 calls)
Cantor Fitzgerald - Reiterated
Overweight → Overweight 2026-07-01 40% win rate (10 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-06-08 33% win rate (6 calls)
Chardan Capital - Reiterated
Buy → Buy 2026-03-27 33% win rate (6 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
8/30
Consensus clarity
13/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →